Navigation Links
Zogenix Reports FDA Provides New PDUFA Date for Sumavel(TM) DosePro(TM)
Date:2/18/2009

ith the FDA to help make this important alternative treatment available to patients who suffer from migraines," said Roger L. Hawley, Chief Executive Officer of Zogenix. "We are building commercial inventory and our launch plans are in place. It is our intention to launch the product following FDA approval in the second half of 2009."

About Zogenix

Zogenix, Inc., with offices in Emeryville and San Diego, Calif., is a private, specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. The company's lead product candidate, Sumavel DosePro, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine and cluster headache. Zogenix submitted a New Drug Application with the U.S. Food and Drug Administration for Sumavel DosePro in December 2007. The company also plans to license the patented DosePro needle- free drug delivery system to other companies. The company's second product candidate, ZX002, is a novel, oral controlled release formulation of hydrocodone for the treatment of chronic pain. This product candidate has completed Phase 2 clinical trials and is ready to begin Phase 3. For additional information, visit http://www.zogenix.com.

Zogenix(TM), Sumavel(TM), and DosePro(TM) are trademarks of Zogenix, Inc.


'/>"/>
SOURCE Zogenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
2. Gentiva Reports Fourth Quarter and Fiscal 2008 Results
3. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
4. Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009
5. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
6. YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
7. Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results
8. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
9. Corgenix Reports Second Quarter Fiscal 2009 Financial Results
10. Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 16, 2014 “Never say, ‘I ... Universität Marburg’s Department of Physics, advises young women ... newly released SPIE Women in Optics 18-month ... shy to ask questions.” , In the annual ... mathematics) occupations ranging from university professor and laboratory ...
(Date:12/17/2014)... 2014 Ipsen Biopharmaceuticals, Inc., an ... IPSEY), today announced that Somatuline® Depot® ... was approved by the U.S. Food and Drug ... tumors (GEP-NETs) in adult patients with unresectable, well ... to improve progression-free survival (PFS). , “The approval ...
(Date:12/17/2014)... Texas (PRWEB) December 17, 2014 ... on Global Quartz Tubing industry. For an overview ... definition, classification, application, industry chain structure, industry overview, ... quartz tubing industry has witnessed rapid ... a number of acquisitions. This report mentions quartz ...
(Date:12/17/2014)... Park, CA (PRWEB) December 17, 2014 ... announces today that it has entered into a ... Midland Company (ADM) to apply DNA2.0’s proprietary protein ... enzyme engineering process. , “We are extremely excited ... ProteinGPS engineering platform. This proprietary bioengineering technology ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 82020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
... a Conference Call Today To Discuss the Data and Ongoing ... Clinical Development Programs, ... ) announced today top-line data from its,SB-509-601 clinical trial, one of ... develop SB-509 for diabetic,neuropathy (DN). The data demonstrate that repeat administration ...
... HDL functionality are distinguishing factors, ... LA, Nov. 10 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix") ... scientific data,was presented in an oral presentation ... American Heart Association Scientific Meeting. The,presentation titled ...
... of transport of key amyloid marker from ... Nov. 10 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix") (TSX:RVX) announced ... first in class ApoA-I/Prebeta-HDL elevating drug, in a ... that treatment with RVX-208,resulted in a positive trend ...
Cached Biology Technology:Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 4Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 5Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 6RVX-208 Data Demonstrates Increase in Functional HDL Particles 2RVX-208 Data Demonstrates Increase in Functional HDL Particles 3RVX-208 Data Demonstrates Increase in Functional HDL Particles 4RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 2RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 3RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 4
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... on the rise and more than 120 countries now ... right to create a new, specialized global environmental agency, ... a keynote address to government ministers meeting Tuesday in ... Minister of Malaysia and former co-chair of the UN ...
... science program for Euroscience Open Forum 2012 (ESOF 2012) was ... 2012 will take place in Dublin this year from 11th ... in Europe, will be held in the heart of the ... ESOF is an interdisciplinary, pan-European meeting, held under the auspices ...
... Vicious, winner-take-all competition in nature is an essential pillar ... people have about how, or whether, to teach the ... science and religion are in deliberate opposition, like two ... and practicing Catholic Kenneth Miller teaches evolution, he also ...
Cached Biology News:Create effective new global environmental agency, ministers urged 2Create effective new global environmental agency, ministers urged 3Science Program announced for Euroscience Open Forum 2012 in Dublin 2Science Program announced for Euroscience Open Forum 2012 in Dublin 3Science Program announced for Euroscience Open Forum 2012 in Dublin 4Science Program announced for Euroscience Open Forum 2012 in Dublin 5Teaching science to the religious? Focus on how theories develop 2Teaching science to the religious? Focus on how theories develop 3
...
...
... The newest member of Wyatt Technology's ... fits inside of your high temperature chromatograph ... scattering data from thermoplastic polymers. The HTmD ... any Waters 150C, PL220C or Alliance 2000 ...
...
Biology Products: